← Insights

Pharmaceutical Regulations in the UAE: 2025 Update

Understand the latest pharmaceutical regulations in the UAE to ensure compliant and innovative operations in the evolving 2025 healthcare sector.

A guide to running pharmaceutical business operations within the UAE’s updated regulatory framework while staying compliant and competitive.

Reviewed by Mohamed Noureldin, Founder, Managing Partner & Senior Legal Consultant

Navigating the New Era: Pharmaceutical Regulations in the UAE (2025 Update)

The United Arab Emirates (UAE) is a global hub for business and innovation, and it is increasingly a leader in healthcare and pharmaceuticals. As the country moves toward a knowledge-based economy, pharmaceutical regulations in the UAE are undergoing a significant transformation. The year 2025 marks a new era for the industry, driven mainly by the implementation of the landmark Federal Decree-Law No. (38) of 2024.

Related: Explore our real estate law advisory services in the UAE.

This guide covers the core of the 2025 UAE pharmaceutical regulations. It analyses the new legal framework, the role of the Emirates Drug Establishment (EDE), and the critical compliance requirements for pharmaceutical companies, manufacturers and distributors operating in the Emirates.

The Foundation: Federal Decree-Law No. (38) of 2024

For businesses in the sector, the new Decree-Law changes how products reach the market and how establishments operate. This article explains its main requirements so that you can protect your position and plan for compliance.

Effective from January 2, 2025, Federal Decree-Law No. (38) of 2024 repeals the previous Federal Law No. (8) of 2019 and introduces a robust, centralised and modern regulatory structure. The legislation is designed to enhance the safety, efficacy and quality of medical products while fostering innovation and investment in the local pharmaceutical industry.

Related: Explore our labour and employment law advisory services in the UAE.

The Decree-Law's scope is extensive, covering:

  • Medical Products: Including pharmaceuticals, biopharmaceuticals, advanced medical treatment products, medical equipment, food supplements and cosmetics.
  • Pharmaceutical Establishments: Such as pharmacies, medical warehouses, marketing offices and manufacturing factories.
  • The Pharmacy Profession: Regulating the practice of pharmacists and related professionals.

The central authority overseeing this framework is the Emirates Drug Establishment (EDE). It has been granted broad powers to regulate every stage of the medical product lifecycle, from manufacturing and registration to pricing and pharmacovigilance.

The Central Regulator: Emirates Drug Establishment (EDE)

The establishment of the EDE, following Federal Decree-Law No. (28) of 2023, reflects the UAE's commitment to a unified and efficient regulatory system. The EDE is the sole federal body responsible for granting all types of approvals and licences related to medical products in the UAE.

Key Responsibilities of the EDE

  • Marketing Approval (Registration): Granting and renewing all types of Marketing Approvals (MA) for medical products, including innovative, generic and orphan products.
  • Pricing: Determining the price of medical products sold to the public, ensuring fair access and market stability.
  • Licensing: Issuing licences for all pharmaceutical establishments, including factories, warehouses and marketing offices.
  • Pharmacovigilance: Establishing and managing a national system for monitoring the safety and adverse effects of medical products after they are marketed.
  • Inspection and Enforcement: Conducting inspections and imposing administrative and disciplinary penalties for non-compliance.

For professional legal guidance, see our corporate governance and business compliance advisory, contract drafting services and crypto regulation compliance advisory service pages.

Critical Pharmaceutical Regulations in the UAE for 2025

Compliance with the new Decree-Law depends on a clear understanding of the revised requirements for product registration, establishment licensing and operational conduct.

1. Marketing Approval (Product Registration)

The Decree-Law sets out several pathways for product registration, reflecting a more nuanced approach to market entry:

  • Standard Marketing Approval (MA): Valid for five years and renewable, this is the standard route for most medical products.
  • Conditional Marketing Approval: Issued for products where comprehensive data is pending, often those with high therapeutic value but limited clinical experience.
  • Emergency Use Approval: A fast-track mechanism for medical products required during a health emergency or pandemic.
  • Fast Track Marketing Approval: Simplified procedures for innovative medical products of therapeutic importance, encouraging rapid market access for new treatments.

A critical requirement is that no medical product may be imported, distributed or manufactured for circulation in the UAE without obtaining the relevant Marketing Approval from the EDE.

2. Licensing of Pharmaceutical Establishments

The licensing framework is highly detailed. It covers everything from general pharmacies and chains to specialised biobanks and research entities. The law mandates that all establishments must obtain a licence from the EDE and adhere to specific Good Practice (GP) standards, such as Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP).

The licensing process is complex. It requires careful preparation of documents, including facility plans, quality management systems and personnel qualifications. For any entity looking to establish a presence in the UAE's pharmaceutical sector, meeting these licensing requirements is essential.

Expert Legal Insight: The shift to a centralised EDE licensing system streamlines the process but also raises the bar for compliance. Companies must ensure their applications are complete and accurate and that their operating procedures meet the highest international standards. For comprehensive support with pharmaceutical establishment licensing and regulatory compliance, it is advisable to consult experienced legal professionals such as Nour Attorneys & Legal Consultants to ensure a smooth and successful market entry.

3. Pharmacovigilance and Product Safety

The new legislation places a strong emphasis on pharmacovigilance: the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.

Key requirements include:

  • Mandatory Reporting: Marketing Rights Holders are obligated to report all adverse reactions, side effects and quality defects to the EDE's national pharmacovigilance system.
  • Risk Management Plans: Companies must submit and maintain robust risk management plans for their products.
  • Product Withdrawal: The EDE has the authority to suspend or withdraw a product's Marketing Approval if safety concerns arise or if the product is found to be unfit for consumption, adulterated or smuggled.

4. Regulation of Controlled and Semi-Controlled Substances

The Decree-Law sets stringent rules for handling controlled and semi-controlled materials and products, as well as chemical precursors. These measures are designed to prevent misuse and keep supply chains secure.

  • Strict Controls: The law specifies conditions for the preservation, circulation, import and export of these substances, requiring detailed records and periodic inventory checks.
  • Prohibitions: Severe penalties are in place for the illegal circulation, possession or sale of controlled substances.

Fostering Innovation: Intellectual Property and Research

To position the UAE as a research and development (R&D) hub, the new law includes provisions that protect intellectual property and encourage clinical research.

  • IP Protection: The law explicitly mandates the protection of intellectual property rights related to medical products, aligning with international standards and providing a secure environment for innovative companies.
  • Clinical Trials: The EDE regulates non-clinical and clinical research and requires approval for all trials conducted within the UAE to ensure ethical standards and scientific rigour. The law also provides for the licensing of specialised entities for research and bioequivalence studies.

The Importance of Legal Counsel in the New Regulatory Climate

The transition to Federal Decree-Law No. (38) of 2024 is a significant regulatory overhaul. The changes are designed to be beneficial, promoting quality, safety and innovation, but they also introduce new complexities and higher compliance burdens for businesses.

The penalties for non-compliance are severe. They range from administrative fines and licence suspension to criminal sanctions for serious violations such as the circulation of unapproved or counterfeit products.

For pharmaceutical companies, manufacturers and distributors, proactive legal guidance is no longer optional; it is a necessity. Experienced legal counsel can provide valuable support in several critical areas:

  • Regulatory Compliance Audits: Reviewing existing operations against the new EDE requirements (Decree-Law No. 38 of 2024) to identify and close compliance gaps.
  • Marketing Approval Applications: Preparing and submitting complete, accurate applications for Standard, Conditional or Fast Track Marketing Approvals to the EDE.
  • Establishment Licensing: Guiding the complex process of obtaining licences for factories, warehouses and marketing offices, ensuring adherence to Good Practice standards.
  • Contract Drafting and Review: Negotiating and drafting commercial contracts, distribution agreements and R&D partnerships that comply with UAE law.
  • Dispute Resolution: Representing clients in administrative appeals against EDE decisions or in commercial disputes related to pharmaceutical trade.

Actionable Advice: Given the intricate nature of the new regulations, particularly on product registration, pricing and the handling of controlled substances, securing specialised legal support is the most prudent step. Nour Attorneys & Legal Consultants offers dedicated legal services in the UAE, providing the expertise needed to navigate this evolving regulatory landscape and keep your business fully compliant and well positioned for growth.

Conclusion

The UAE's Federal Decree-Law No. (38) of 2024 is a bold step towards a world-class pharmaceutical ecosystem. It centralises authority under the Emirates Drug Establishment (EDE), introduces modern approval pathways and strengthens safety measures through rigorous pharmacovigilance.

For all stakeholders in the pharmaceutical industry, 2025 is a year of adaptation and strict compliance. Understanding Marketing Approval, establishment licensing and the increased focus on product safety is crucial for sustained success in the UAE market. By working with experienced legal advisers, companies can meet these new challenges with confidence, take advantage of the opportunities for innovation and contribute to the UAE's vision of a healthier, more advanced future.

References

  • Federal Decree-Law No. (38) of 2024 Governing Medical Products, Pharmacists and Pharmaceutical Establishments. UAE Legislation. https://uaelegislation.gov.ae/en/legislations/2751
  • Nour Attorneys & Legal Consultants. Types of Licenses and Activities for Companies in Dubai, UAE. https://nourattorneys.com/types-of-license-and-activities-for-companies-in-dubai-uae/
  • Nour Attorneys & Legal Consultants. Medical Malpractice Law UAE. https://nourattorneys.com/medical-malpractice-law-uae/
  • Nour Attorneys & Legal Consultants. Official Website. https://nourattorneys.com/

Related Services: Explore our tax consultancy services, including economic substance regulations in the UAE and real estate law advisory, including RERA regulations in Dubai, for practical legal support in this area.

Disclaimer: The information provided in this article is for general informational purposes only and does not constitute legal advice. Readers should seek professional legal advice tailored to their specific circumstances before making any decisions or taking any action based on the content of this article.

Nour Attorneys Team

Additional Resources

Explore more of our insights on related topics:

Call Us NowChat With Our Team On WhatsApp